PSAs of all base-case and scenario analyses across all accepted willingness-to-pay thresholds in the United States
| Willingness-to-pay threshold (USD/QALY) . | Rapid Base-case | ∗Scenario . | In-house Base-case | ∗Scenario . | Send-out Base-case | ∗Scenario . |
|---|---|---|---|
| PLASMIC = 5 (intermediate), TPE with caplacizumab | |||
| 50 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| 100 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| 150 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| PLASMIC = 5 (intermediate), TPE without caplacizumab | |||
| 50 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| 100 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| 150 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| PLASMIC = 6 or 7 (high), TPE with caplacizumab | |||
| 50 000 | 99.94% | 99.94% | 0.06% | 0.06% | 0% | 0% |
| 100 000 | 99.94% | 99.94% | 0.06% | 0.06% | 0% | 0% |
| 150 000 | 99.94% | 99.94% | 0.06% | 0.06% | 0% | 0% |
| PLASMIC = 6 or 7 (high), TPE without caplacizumab | |||
| 50 000 | 98.81% | 98.81% | 1.19% | 1.19% | 0% | 0% |
| 100 000 | 98.81% | 98.81% | 1.19% | 1.19% | 0% | 0% |
| 150 000 | 98.81% | 98.81% | 1.19% | 1.19% | 0% | 0% |
| Willingness-to-pay threshold (USD/QALY) . | Rapid Base-case | ∗Scenario . | In-house Base-case | ∗Scenario . | Send-out Base-case | ∗Scenario . |
|---|---|---|---|
| PLASMIC = 5 (intermediate), TPE with caplacizumab | |||
| 50 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| 100 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| 150 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| PLASMIC = 5 (intermediate), TPE without caplacizumab | |||
| 50 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| 100 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| 150 000 | 100% | 100% | 0% | 0% | 0% | 0% |
| PLASMIC = 6 or 7 (high), TPE with caplacizumab | |||
| 50 000 | 99.94% | 99.94% | 0.06% | 0.06% | 0% | 0% |
| 100 000 | 99.94% | 99.94% | 0.06% | 0.06% | 0% | 0% |
| 150 000 | 99.94% | 99.94% | 0.06% | 0.06% | 0% | 0% |
| PLASMIC = 6 or 7 (high), TPE without caplacizumab | |||
| 50 000 | 98.81% | 98.81% | 1.19% | 1.19% | 0% | 0% |
| 100 000 | 98.81% | 98.81% | 1.19% | 1.19% | 0% | 0% |
| 150 000 | 98.81% | 98.81% | 1.19% | 1.19% | 0% | 0% |
All parameters varied simultaneously over 100 000 Monte Carlo iterations in each sensitivity analysis.
USD, US dollar.
Scenario analyses: all bleeding events (and thus cost of managing them) nullified.